NEWS
Two new publications out
We contributed to a paper on a newly generated reporter line expressing NanoLuciferase. Within two weeks another paper we collaborated on came out about blocking transmission of gametocytes. Read more ...
Collaboration leads to breakthrough insights in olfactory representation
In a collaboration with Google Research and Osmo, TropIQ contributed to a landmark paper that provides fundamental insights into the relationship between odors. It demonstrates that perceptual similarity is related ...
Miniaturized sporozoite assays identify antimalarials acting on liver schizogony
We investigated how susceptible the early stages of malaria are to chemical treatments, and we created a screening strategy to identify new drugs that can prevent infection. The results are published in ...
TropIQ contributes to arresting growth late in the liver
TropIQ assessed drug sensitivity of a new genetically attenuated malaria parasite that qualifies as a vaccine candidate. The results of these studies have been now been published in NPJ Vaccines ...
TropIQ presents at the Drug Design and Development seminar in Munich
TropIQ will contribute two oral presentations to the 2022 Drug Design and Development Seminar of the German Society for Parasitology: Analysis of tick regurgitation following mechanical, cryogenic and chemical removal ...
MMV, PPSC and TropIQ present a webinar on state of the art in malaria phenotypic screening
On June 22nd at 4 pm CET, the Medicines for Malaria Venture, the Pivot Park Screening Centre and TropIQ will present a webinar on their collaborative work in malaria phenotypic ...
Antimalarial MMV’183 is a clinical development candidate
TropIQ's parasitology platform drove the optimisation of pantothenamide compounds that generated MMV'183: a candidate for further clinical development with a new mode of action for treatment of malaria and blocking transmission ...
TropIQ publishes innovative mosquito barcoding technology
We present a barcoding strategy that enables phenotypic screens of blood-feeding insects against small molecules in microtiter plate-based arrays and apply this to discovery of novel systemic insecticides and compounds ...
TropIQ awarded large research grant to uncover new mosquito repellents.
Together with researchers from the University of Washington, TropIQ was awarded 1.3 million USD from the Bill & Melinda Gates Foundation to find new mosquito repellents and thus aid the ...
MalDA prioritises malaria drug targets with TropIQ’s input
The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further advocates target ...
Our team aids the discovery of a new anti-malarial scaffold.
Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria drug. read ...
Review of MalDA’s scientific achievements just released
TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation to advance ...
Our liver stage platform supports life cycle profiling for new anti-malarial.
In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read more here ...
TropIQ assists in life cycle profiling of genetically modified chimeric Plasmodium parasite.
To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was generated. This ...
TropIQ Digitalises Its Discovery Platform with CDD Vault
CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time Nijmegen and San Francisco — October 8, 2020 TropIQ Health Sciences, a biotechnology ...
TropIQ contributes to research on malaria vaccine
Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length PfCSP which ...
Dr. Sheshachalam is joining TropIQ
Dr. Sheshachalam has joined the team as a Scientist. He is an experienced cell biologist with a broad expertise in immunology, molecular biology and drug discovery. He obtained his PhD ...
